AnaptysBio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 117
- Market Cap
- $1.1B
- Website
- http://www.anaptysbio.com
- Introduction
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: RosnilimabDrug: Placebo
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT06127043
- Locations
- 🇺🇸
AnaptysBio Investigative Site 10-114, Sun City, Arizona, United States
🇬🇪AnaptysBio Investigative Site 59-106, Tbilisi, Georgia
🇺🇸AnaptysBio Investigative Site 10-112, Lancaster, California, United States
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: RosnilimabDrug: Placebo
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT06041269
- Locations
- 🇮🇹
AnaptysBio Investigative Site 20-106, Milan, Lombardy, Italy
🇮🇹AnaptysBio Investigative Site 20-110, Milan, Italy
🇺🇸AnaptysBio Investigative Site 10-132, Flagstaff, Arizona, United States
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
- Conditions
- Atopic Dermatitis Eczema
- Interventions
- Drug: ANB032Drug: Placebo
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05935085
- Locations
- 🇺🇸
AnaptysBio Investigative Site 10-148, Las Vegas, Nevada, United States
🇺🇸AnaptysBio Investigative Site 10-107, Fremont, California, United States
🇺🇸AnaptysBio Investigative Site 10-136, Doral, Florida, United States
Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Biological: ImsidolimabOther: Placebo
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05366855
- Locations
- 🇺🇸
Site 109, Largo, Florida, United States
🇺🇸Site 102, Springville, Utah, United States
🇫🇷Site 16-101, Paris, France
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05352893
- Locations
- 🇺🇸
Site 102, Springville, Utah, United States
🇲🇾Site 42101, Kuala Lumpur, Malaysia
🇲🇾Site 42102, Muar, Malaysia
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
- Conditions
- Alopecia Areata
- Interventions
- Biological: PlaceboBiological: Rosnilimab
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05205070
- Locations
- 🇺🇸
10-105, Birmingham, Alabama, United States
🇺🇸Site 10-111, New York, New York, United States
🇺🇸Site10-103, Encinitas, California, United States
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Biological: ImsidolimabBiological: Placebo Solution
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT04856930
- Locations
- 🇬🇪
Site 59-106, Batumi, Georgia
🇬🇪Site 59-102, Tbilisi, Georgia
🇵🇱Site 30-106, Olsztyn, Poland
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT04856917
- Locations
- 🇺🇸
Site 10-111, Fountain Valley, California, United States
🇺🇸Site 10-104, Detroit, Michigan, United States
🇺🇸Site 10-101, San Antonio, Texas, United States
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
- Conditions
- Acneiform Eruptions
- Interventions
- Biological: PlaceboBiological: Imsidolimab
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04697069
- Locations
- 🇬🇪
Site 402, Tbilisi, Georgia
🇱🇻Site 601, Riga, Latvia
🇺🇸Site 103, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04697056
- Locations
- 🇺🇸
Site 102, Columbus, Ohio, United States
🇺🇸Site 101, Chicago, Illinois, United States
🇺🇸Site 106, Palo Alto, California, United States